دورية أكاديمية
أعرض في EDS

Detection of oxaliplatin- and cisplatin-DNA lesions requires different global genome repair mechanisms that affect their clinical efficacy.

التفاصيل البيبلوغرافية
العنوان: Detection of oxaliplatin- and cisplatin-DNA lesions requires different global genome repair mechanisms that affect their clinical efficacy.
المؤلفون: Slyskova J; Center for Cancer Research, Medical University of Vienna, A-1090 Vienna, Austria.; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, A-1090 Vienna, Austria., Muniesa-Vargas A; Department of Molecular Genetics, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands., da Silva IT; Laboratory of Bioinformatics and Computational Biology, A.C. Camargo Cancer Center, São Paulo 01508-010, Brazil., Drummond R; Laboratory of Bioinformatics and Computational Biology, A.C. Camargo Cancer Center, São Paulo 01508-010, Brazil., Park J; Center for Genomic Integrity, Institute for Basic Science, Ulsan 44919, Republic of Korea., Häckes D; Department of Molecular Genetics, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands., Poetsch I; Center for Cancer Research, Medical University of Vienna, A-1090 Vienna, Austria.; Research Cluster 'Translational Cancer Therapy Research', A-1090 Vienna, Austria., Ribeiro-Silva C; Department of Molecular Genetics, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands., Moretton A; Center for Cancer Research, Medical University of Vienna, A-1090 Vienna, Austria.; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, A-1090 Vienna, Austria., Heffeter P; Center for Cancer Research, Medical University of Vienna, A-1090 Vienna, Austria.; Research Cluster 'Translational Cancer Therapy Research', A-1090 Vienna, Austria., Schärer OD; Center for Genomic Integrity, Institute for Basic Science, Ulsan 44919, Republic of Korea.; Department of Biological Sciences, Ulsan National Institute of Science and Technology, Ulsan 44919, Republic of Korea., Vermeulen W; Department of Molecular Genetics, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands., Lans H; Department of Molecular Genetics, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3015 GD Rotterdam, The Netherlands., Loizou JI; Center for Cancer Research, Medical University of Vienna, A-1090 Vienna, Austria.; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, A-1090 Vienna, Austria.
المصدر: NAR cancer [NAR Cancer] 2023 Dec 05; Vol. 5 (4), pp. zcad057. Date of Electronic Publication: 2023 Dec 05 (Print Publication: 2023).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 101769553 Publication Model: eCollection Cited Medium: Internet ISSN: 2632-8674 (Electronic) Linking ISSN: 26328674 NLM ISO Abbreviation: NAR Cancer Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Oxford : Oxford University Press, [2019]-
مستخلص: The therapeutic efficacy of cisplatin and oxaliplatin depends on the balance between the DNA damage induction and the DNA damage response of tumor cells. Based on clinical evidence, oxaliplatin is administered to cisplatin-unresponsive cancers, but the underlying molecular causes for this tumor specificity are not clear. Hence, stratification of patients based on DNA repair profiling is not sufficiently utilized for treatment selection. Using a combination of genetic, transcriptomics and imaging approaches, we identified factors that promote global genome nucleotide excision repair (GG-NER) of DNA-platinum adducts induced by oxaliplatin, but not by cisplatin. We show that oxaliplatin-DNA lesions are a poor substrate for GG-NER initiating factor XPC and that DDB2 and HMGA2 are required for efficient binding of XPC to oxaliplatin lesions and subsequent GG-NER initiation. Loss of DDB2 and HMGA2 therefore leads to hypersensitivity to oxaliplatin but not to cisplatin. As a result, low DDB2 levels in different colon cancer cells are associated with GG-NER deficiency and oxaliplatin hypersensitivity. Finally, we show that colon cancer patients with low DDB2 levels have a better prognosis after oxaliplatin treatment than patients with high DDB2 expression. We therefore propose that DDB2 is a promising predictive marker of oxaliplatin treatment efficiency in colon cancer.
(© The Author(s) 2023. Published by Oxford University Press on behalf of NAR Cancer.)
References: Biochemistry. 2007 Jun 5;46(22):6477-87. (PMID: 17497831)
Nat Methods. 2016 Jul;13(7):577-80. (PMID: 27240256)
J Biol Chem. 2014 Sep 26;289(39):27278-27289. (PMID: 25118285)
Int J Mol Sci. 2020 Dec 04;21(23):. (PMID: 33291532)
Nucleic Acids Res. 2005 Jul 19;33(13):4023-34. (PMID: 16030353)
JAMA. 2021 Sep 7;326(9):851-862. (PMID: 34547082)
Met Ions Life Sci. 2018 Feb 5;18:. (PMID: 29394020)
Transl Oncol. 2021 Jan;14(1):100894. (PMID: 33069103)
Proc Natl Acad Sci U S A. 2016 Oct 11;113(41):11507-11512. (PMID: 27688757)
Nucleic Acids Res. 2014 Dec 16;42(22):e168. (PMID: 25300484)
J Mol Biol. 2004 Aug 27;341(5):1251-69. (PMID: 15321720)
Cell Death Dis. 2021 May 13;12(5):485. (PMID: 33986248)
Nat Methods. 2020 Jul;17(7):708-716. (PMID: 32514112)
Nat Rev Mol Cell Biol. 2014 Jul;15(7):465-81. (PMID: 24954209)
Cell. 2011 Nov 23;147(5):1024-39. (PMID: 22118460)
J Cell Sci. 2008 Sep 1;121(Pt 17):2850-9. (PMID: 18682493)
Nat Commun. 2022 Feb 21;13(1):974. (PMID: 35190564)
J Gastrointest Oncol. 2019 Dec;10(6):1183-1192. (PMID: 31949938)
Nat Commun. 2014 Apr 28;5:3695. (PMID: 24770583)
Am J Health Syst Pharm. 2009 Nov 1;66(21):1929-33. (PMID: 19850787)
J Synchrotron Radiat. 2001 Mar 1;8(Pt 2):716-8. (PMID: 11512906)
Nucleic Acids Res. 2002 Jan 1;30(1):207-10. (PMID: 11752295)
Oncogenesis. 2013 Sep 16;2:e71. (PMID: 24042735)
Cancers (Basel). 2021 Apr 25;13(9):. (PMID: 33922989)
Genome Biol. 2014;15(12):550. (PMID: 25516281)
Cell Death Dis. 2014 May 29;5:e1257. (PMID: 24874729)
Cell. 2005 May 6;121(3):387-400. (PMID: 15882621)
DNA Repair (Amst). 2005 Jul 28;4(8):926-38. (PMID: 15916927)
Cell Rep. 2017 Oct 31;21(5):1375-1385. (PMID: 29091773)
Chem Rev. 2007 May;107(5):1387-407. (PMID: 17455916)
Front Pharmacol. 2020 Mar 20;11:343. (PMID: 32265714)
Nucleic Acids Res. 2019 Apr 23;47(7):3536-3549. (PMID: 30698791)
DNA Repair (Amst). 2021 Oct;106:103192. (PMID: 34358806)
Cancer Res. 1999 Aug 15;59(16):3968-71. (PMID: 10463593)
Pharm Res. 2004 May;21(5):891-4. (PMID: 15180350)
Nucleic Acids Res. 2009 Jul;37(13):4371-84. (PMID: 19465398)
J Biol Chem. 2020 May 29;295(22):7584-7594. (PMID: 32299912)
Nucleic Acids Res. 2019 Jul 9;47(12):6015-6028. (PMID: 31106376)
J Biol Chem. 2005 Dec 2;280(48):39982-9. (PMID: 16223728)
Curr Protoc. 2021 Mar;1(3):e90. (PMID: 33780170)
Nucleic Acids Res. 2003 Dec 1;31(23):6841-51. (PMID: 14627817)
Biostatistics. 2017 Apr 1;18(2):275-294. (PMID: 27756721)
Cold Spring Harb Perspect Biol. 2013 Oct 01;5(10):a012609. (PMID: 24086042)
Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):424-8. (PMID: 9892649)
Bioinformatics. 2016 Sep 15;32(18):2847-9. (PMID: 27207943)
Nucleic Acids Res. 2019 Jul 02;47(W1):W171-W174. (PMID: 31106371)
Annu Rev Biochem. 2021 Jun 20;90:107-135. (PMID: 33882259)
Lancet. 2006 Mar 4;367(9512):754-65. (PMID: 16517276)
J Biol Chem. 2002 Jan 18;277(3):1637-40. (PMID: 11705987)
Cell Mol Life Sci. 2021 Dec;78(24):7925-7942. (PMID: 34731255)
Nucleic Acids Res. 2018 Oct 12;46(18):9537-9549. (PMID: 30137419)
DNA Repair (Amst). 2016 Aug;44:110-117. (PMID: 27264556)
Genes (Basel). 2021 Feb 13;12(2):. (PMID: 33668453)
G3 (Bethesda). 2017 Aug 07;7(8):2719-2727. (PMID: 28655737)
Nat Methods. 2014 Aug;11(8):783-784. (PMID: 25075903)
Nat Rev Cancer. 2007 Aug;7(8):573-84. (PMID: 17625587)
Bioinformatics. 2013 Jan 1;29(1):15-21. (PMID: 23104886)
Cell Mol Life Sci. 2002 Nov;59(11):1914-27. (PMID: 12530522)
J Biol Chem. 2003 Jan 17;278(3):1769-73. (PMID: 12429734)
Nat Genet. 2018 Aug;50(8):1132-1139. (PMID: 30054595)
J Biol Chem. 2000 Jul 14;275(28):21422-8. (PMID: 10777490)
Cell. 2008 Dec 26;135(7):1213-23. (PMID: 19109893)
Nat Commun. 2020 Sep 28;11(1):4868. (PMID: 32985517)
Nat Commun. 2018 Oct 4;9(1):4067. (PMID: 30287812)
Biochem Pharmacol. 2005 Dec 5;70(12):1717-25. (PMID: 16259963)
Cancer Lett. 2014 May 1;346(2):163-71. (PMID: 24462818)
Mol Cancer. 2010 Sep 16;9:248. (PMID: 20846399)
DNA Repair (Amst). 2018 Nov;71:33-42. (PMID: 30174301)
Chem Rev. 2006 Feb;106(2):253-76. (PMID: 16464005)
Front Cell Dev Biol. 2014 Mar 06;2:5. (PMID: 25364713)
Nat Rev Cancer. 2021 Jan;21(1):37-50. (PMID: 33128031)
DNA Repair (Amst). 2015 Nov;35:126-36. (PMID: 26519826)
Genes Dev. 2001 Mar 1;15(5):507-21. (PMID: 11238373)
Mol Cell. 2000 Apr;5(4):737-44. (PMID: 10882109)
Nat Rev Cancer. 2007 Dec;7(12):899-910. (PMID: 18004397)
Biochim Biophys Acta. 2010 Dec;1806(2):172-82. (PMID: 20647037)
Proc Natl Acad Sci U S A. 1994 Oct 25;91(22):10394-8. (PMID: 7937961)
Mol Pharmacol. 2000 Nov;58(5):920-7. (PMID: 11040038)
Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):950-955. (PMID: 28096358)
Nucleic Acids Res. 2002 Jun 1;30(11):2588-98. (PMID: 12034848)
Cold Spring Harb Perspect Biol. 2011 Jan 01;3(1):a000745. (PMID: 20980439)
Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):E2737-46. (PMID: 22822215)
Nat Rev Mol Cell Biol. 2019 Dec;20(12):766-784. (PMID: 31558824)
Nucleic Acids Res. 2015 Feb 18;43(3):1700-13. (PMID: 25628365)
تواريخ الأحداث: Date Created: 20231207 Latest Revision: 20240325
رمز التحديث: 20240325
مُعرف محوري في PubMed: PMC10696645
DOI: 10.1093/narcan/zcad057
PMID: 38058548
قاعدة البيانات: MEDLINE
الوصف
تدمد:2632-8674
DOI:10.1093/narcan/zcad057